90.43
+0.06%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Solventum
From its filings with the US Securities and Exchange Commission
Solventum is based in Eagan, Minnesota and is incorporated in Delaware. Its shares trade on NYSE under the ticker SOLV. It is a member of the S&P 500. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $8.32bn and net income of $1.56bn. At that date it held total assets of $14.29bn and shareholders' equity of $5.05bn.
Solventum Corporation ("Solventum," "we," "our," "us," or the "Company"), is a leading global healthcare company developing, manufacturing, and commercializing a broad portfolio of solutions that leverages deep material science, data science, and digital capabilities to address critical customer and patient needs. We constantly seek to enable the improvement of standards of care and move healthcare forward with innovation powered by insights, clinical intelligence, technology, and manufacturing expertise. Our 70+ year history of discovering and innovating advanced solutions has helped us solve our customers’ toughest challenges.
Our solutions are relied on every day within the global healthcare industry to deliver higher-quality patient care, more efficient processes and workflows, and improved standards of safety and accuracy. Additionally, our products and services are present along a patient’s journey through prevention, diagnosis, treatment, and recovery.
Our business possesses strong customer relationships, a broad, wide-ranging, and well-known portfolio of brands, differentiated technology, and manufacturing expertise. We serve a diverse customer base, ranging from multidisciplinary hospitals to local clinics/practices. Our long-tenured and collaborative customer relationships globally give us unique insights into their needs and preferences. These insights inform our innovation processes, drive stronger customer retention, and create multiple avenues for further customer engagement.
Quoted from its 10-K, filed 27 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 26 Mar 2024
- Employees
- 10,000
- Head office
- 1750 YANKEE DOODLE ROAD, EAGAN, MN, 55121
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Ms. Carrie CoxIndependent Chairman of the Board$852,500
- Mr. Bryan HansonChief Executive Officer, Director, since 2024$40.0m
- Mr. Wayde McMillanChief Financial Officer$10.3m
- Ms. Garri GarrisonPresident - Health Information Systems
- Mr. Vaughn GrannisPresident - Purification and Filtration
- Mr. Karim MansourPresident - Dental Solutions
- Ms. Tammy GomezChief Human Resources Officer$5.0m
- Mr. Chris BarryExecutive Vice President and Group President, Medical Surgical$9.8m
- Ms. Amy LanducciChief Information and Digital Officer$9.1m
- Mr. Sanjiv AroraChief Strategy & Corporate Development Officer
- Mr. Paul HarringtonChief Supply Chain Officer
- Ms. Marcela KirbergerChief Legal Affairs Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 71
- Environment
- 77
- Social
- 99
- Governance
- 36
- Direct emissions (scope 1)
- 146,000 t
- Energy emissions (scope 2)
- 104,000 t
- Value chain emissions (scope 3)
- 1,720,000 t
- Women in the workforce
- 46.2%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Solventum Corp has 10,000 employees supporting its US operations.
- The company's IPO on March 26, 2024, provided significant capital.
- Headquartered in St. Paul, Minnesota, the company benefits from a strategic location.
Weaknesses
- The company's limited market presence in international regions is a concern.
- Solventum Corp's reliance on the US market poses a risk.
- The company has no established presence in the European market.
Opportunities
- Expanding into the European market offers new growth potential.
- The US market continues to show strong demand for Solventum Corp's services.
- The company can leverage its IPO capital for strategic acquisitions.
Threats
- Increased competition in the US market threatens Solventum Corp's position.
- Economic downturns in the US could impact the company's performance.
- Regulatory changes in the US may affect Solventum Corp's operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.